Strategic Partnership

Advanced Medical Solutions Grp PLC
19 June 2003


For Immediate Release:                            07:00 Thursday 19th June, 2003



         Advanced Medical Solutions Group plc ('AMS' or the 'Company')

 and ASO Corporation ('ASO') announce a strategic partnership for the supply of
    store-value products in the consumer markets of North America and Japan


Winsford, UK: AMS and ASO, global woundcare technology companies, announced
today that they have entered into a collaboration to supply products into the
consumer store-value brand markets in North America and Japan. Store-value
brands typically represent 20-30% of retail product market share in any
particular category, sold under the retailers own label or value label alongside
the premium branded products.


ASO, a leading manufacturer & marketer of store-value brand products based in
Florida-USA, is a key supplier for many of the leading retail pharmacy chains
such as Walgreens and CVS as well as mass retailers such as Walmart.


The store-value brand market represents a significant opportunity to AMS. As
awareness of the benefits of AMS's products and technologies has increased, so
has consumer demand for these products. The strategic partnership of AMS and ASO
will ensure that AMS has a significant penetration in the store-value markets.
This collaboration will complement the supply relationships that AMS currently
enjoys with major international partners such as Beiersdorf, Johnson & Johnson
Consumer and Novartis Consumer Health.


Initially, AMS will supply its proprietary polyurethane membrane material for
scar treatment, which ASO will convert and package in a variety of
configurations driven by the needs of specific retailers. Scar treatment is a
high growth sector and is attracting significant interest from the retail
market. Scarring represents a huge area of unmet medical need. In addition to
accidental traumas, up to 16% of surgical interventions produce raised,
inflexible, red scar tissue, which is cosmetically very undesirable. It is
estimated that 12% of the population have a scar they would like to treat.


The AMS scar treatment product, currently selling well in Europe, has
demonstrated effectiveness in attenuating scars by flattening scar tissue and
reducing redness. The initial response to this product from the US retail market
has been very positive. A full launch into this market is expected by Qtr. 4
2003.


Commenting on the AMS-ASO collaboration, John Macaskill, CEO of ASO, stated:


'Adding new products and technologies to our growing product line is a core
strategic driver within ASO. We are delighted to partner with a company such as
AMS, which has a record of developing new products from innovative technologies
in the woundcare market. Through this synergistic partnership, we will provide
our retail partners with competitive products in key growth areas. We look
forward to building upon this relationship, by adding more products later this
year.'


Dr. Don Evans, Chief Executive Officer of AMS, said:


'This deal is a very important step for AMS as it continues to build its global
consumer business. There is a significant opportunity to market our products
through store-value brand channels alongside the brand leaders and ASO are an
ideal strategic partner for accessing these opportunities.'


- ENDS -


For further information, please contact:

Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com
------------------

Buchanan Communications                                Tel: [phone]
Nicola How / Fergus Mellon


Notes to Editors:


Advanced Medical Solutions is a leading company in the development and
manufacture of products for the £15 billion global woundcare market.


Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.


In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.


The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to A & E
departments or through distributors.


AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.


ASO Corporation is a recognized global leader in the manufacture, marketing and
sales of wound care products. Its corporate offices are located in Sarasota,
Florida.


Aso Corporation is a subsidiary of Aso International, for more than 50 years a
worldwide leader in the manufacturing and sales of first aid, wound care and
topical pharmaceuticals products. The organization made a major commitment to
the United States market in 1986 when it established Aso Corporation as its US
sales, marketing and manufacturing subsidiary. Today ASO operates state of the
art facilities in Florida-USA, Texas-USA, the Philippines, the Netherlands and
Japan. Aso Corporation is one of the largest US suppliers of wound care
products, both in both retail and medical markets.


For more information, visit the Company's website at www.asocorp.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange